Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up
Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
Talcum Powder Cancer Settlement Talks Begin Sept. 4
Categories: Talcum
Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…
Tepezza Hearing Loss Trials Delayed Until Aug 2026
Categories: Tepezza
A series of Tepezza hearing loss lawsuits, which were expected to go before juries next year, will now be delayed. The U.S. District Judge overseeing the multidistrict…
Cencora Directors Settle Opioid Oversight Case for $111M
Categories: Opioids
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…